How can we help?


Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.


Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).


Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.


Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.


Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.


The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products


Bioneer and University of Copenhagen develops a new high-resistance cell line with functional expression of human P-glycoprotein for screening of new drugs

The brain is a challenge for new therapies as it is difficult to create molecules that readily can enter this complex organ. Thus, many efforts are invested in building models simulating how a potential new drug candidate interacts with cells or tissues bordering the brain or cells or tissues in the brain.

Read more
Welcome to Vibeke Dalhoff

Vibeke Dalhoff joined Bioneer on 1 May 2016

Read more
Welcome to Lovisa Sunesson

Lovisa Sunesson, PhD, BD joined Bioneer's Business Development on 1 May 2016.

Read more

Meet us at:

Berzelius symposium 91, August 31 and Sept 1 2016
The subject of the Berzelius meeting is "Precision Medicine in Type 2 diabetes". Find more information
Read more
Bioneer @ CPHI Barcelona Oct 4 - 6 2016
Bioneer exhibits at the pharma business conference CPHI in Barcelona from October 4 to 6, 2016.
Read more
Nordic Life Science Days 14 - 15 Sept 2016
Bioneer attends NLSDays in Stockholm Sept 14 to 15, 2016
Read more
Other places to meet us